Summit Therapeutics

Summit is a UK company focused on the discovery and development of novel drug candidates to treat areas of high unmet medical need. Our strategy focuses on two therapy areas: Duchenne Muscular Dystrophy, a fatal genetic muscle wasting disease and the infectious disease caused by the bacteria C. difficile.
Type
Public
HQ
Milton, GB
Founded
2003
Employees
23 (est)
Summit Therapeutics was founded in 2003 and is headquartered in Milton, GB

Summit Therapeutics Locations

Milton, GB
Cambridge, US

Summit Therapeutics Metrics

Summit Therapeutics Summary

Market capitalization

£98 M

Closing share price

£1.58
Summit Therapeutics's current market capitalization is £98 M.

Summit Therapeutics Financials

We estimate that Summit Therapeutics's revenue is £1.45 M in FY, 2016 which is 32.45% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

£1.84 M£2.15 M£1.45 M

Revenue growth, %

16.5%-32.4%

    Summit Therapeutics Market Value History

    We estimate that Summit Therapeutics's current employees are approximately 25% female and 75% male.

    Summit Therapeutics Online Presence

    Summit Therapeutics News

    Summit Therapeutics Company Life

    You may also be interested in